Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
EuroIntervention. 2022 Apr 1;17(17):e1417-e1424. doi: 10.4244/EIJ-D-21-00464.
Left ventricular outflow tract (LVOT) calcification is known to be associated with adverse outcomes after transcatheter aortic valve implantation (TAVI) in patients receiving first-generation transcatheter heart valves (THV).
The aim of the present study was to assess the prevalence of LVOT calcification as well as its impact on outcomes in a contemporary TAVI patient cohort.
This retrospective single-centre analysis includes 1,207 patients who underwent transfemoral TAVI between 2012 and 2018 and in whom adequate contrast-enhanced multislice computed tomgraphy (MSCT) imaging for quantification of LVOT calcification was available.
Significant LVOT calcification, defined as >10 mm, was present in 37.4% (n=451) of the patient cohort. After applying propensity score matching there was no difference between patients without (w/o; n=358) and with (w; n=358) significant LVOT calcification with respect to baseline clinical characteristics. At 30 days, the composite of all-cause mortality and non-disabling/disabling stroke occurred more often in patients w LVOT calcification compared to those w/o (4.6 vs 10.1%, p=0.008). Moreover, the composite VARC-3 endpoint of device success at 30 days was in favour of patients w/o LVOT calcification (82.2% vs 73.4%, p=0.007). According to Kaplan-Meier analysis, all-cause mortality one year after TAVI was higher in patients w vs w/o LVOT calcification (12.9 vs 21.4 %, p=0.004).
In patients undergoing TAVI, the presence of significant LVOT calcification is common and associated with worse short-term clinical and functional outcomes as well as higher one-year mortality rates compared to patients w/o LVOT calcification.
在接受第一代经导管心脏瓣膜(THV)的患者中,已知左心室流出道(LVOT)钙化与经导管主动脉瓣植入(TAVI)后的不良结局相关。
本研究旨在评估 LVOT 钙化的流行率及其对当代 TAVI 患者队列结局的影响。
这项回顾性单中心分析纳入了 2012 年至 2018 年间接受经股动脉 TAVI 的 1207 例患者,并且这些患者均具有足够的对比增强多层计算机断层扫描(MSCT)图像,用于 LVOT 钙化的定量分析。
在患者队列中,37.4%(n=451)存在显著的 LVOT 钙化(定义为>10mm)。在应用倾向评分匹配后,无显著 LVOT 钙化(n=358)和有显著 LVOT 钙化(n=358)的患者在基线临床特征方面没有差异。在 30 天时,与无 LVOT 钙化的患者相比,有 LVOT 钙化的患者的全因死亡率和非致残/致残性卒中的复合发生率更高(4.6% vs 10.1%,p=0.008)。此外,在 30 天时,设备成功的复合 VARC-3 终点有利于无 LVOT 钙化的患者(82.2% vs 73.4%,p=0.007)。根据 Kaplan-Meier 分析,TAVI 后一年的全因死亡率在有 LVOT 钙化的患者中高于无 LVOT 钙化的患者(12.9% vs 21.4%,p=0.004)。
在接受 TAVI 的患者中,存在显著的 LVOT 钙化较为常见,与无 LVOT 钙化的患者相比,其短期临床和功能结局较差,并且一年死亡率较高。